Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercalcaemia

Abstract

The present invention relates to a combination of a leucine source and at least one unsaturated fatty acid source for prophylactic or therapeutic treatment of hypercalcaemia. The invention further relates to a combination of a leucine source and at least one unsaturated fatty acid source for reducing or avoiding a reduction in bone mineral density in a subject or for in vivo regulating of the blood plasma calcium homeostasis.

1 . A combination of a leucine source and an ω-3 unsaturated fatty acid source for use in a prophylactic or therapeutic treatment of hypercalcaemia. 
     
     
         2 . A combination of a leucine source and an ω-3 unsaturated fatty acid source for use in the reducing of bone mineral loss or for use in the avoiding of a reduction in bone mineral density in a subject or for use in the in vivo regulating of the blood plasma calcium homeostasis in a subject, wherein said subject is a subject suffering from a cancer. 
     
     
         3 . A combination of a leucine source and an ω-3 polyunsaturated fatty acid source for use in the improving appetite and/or for use in the reducing of nausea and/or for use in the reducing of vomiting urges. 
     
     
         4 . A combination according to any preceding claims for use in the reducing of fatigue. 
     
     
         5 . A combination for a use according to any one of the preceding claims, comprising at least one ω-3 polyunsaturated fatty acid source providing an ω-3 polyunsaturated fatty acid selected from the group of eicosapentaenoic acid, docosahexaenoic acid, eicosatetraenoic acid and docosapentaenoic acid. 
     
     
         6 . A combination for use according to any one of the preceding claims, for use in the treatment of a subject suffering from a cancer, in particular a cancer selected from the group of lung cancer, breast cancer, kidney cancer, multiple myeloma cancer, and head and neck cancer. 
     
     
         7 . A combination for use according to any one of the preceding claims, for use in the treatment of excessive calcium release from bone and/or skeletal muscle; and/or for use in the treatment of excessive calcium accumulation due to kidney failure or hyperparathyroidism. 
     
     
         8 . A combination for use according to any one of the preceding claims, wherein the combination is for use in the treatment of a patient subjected to radiotherapy or chemotherapy. 
     
     
         9 . A combination for use according to any one of the preceding claims, wherein the leucine source comprises at least one compound selected from the group of leucine in the form of a free acid (including its zwitter ionic state); leucine salts; peptides comprising one or more leucine units; proteins comprising one or more leucine units; and conjugates of leucine with a conjugating compound other than an amino acid, a protein, or a peptide, which conjugate is capable of being split into the free amino acid (or salt thereof), preferably in the gut or stomach or after absorption in the enterocytes or liver. 
     
     
         10 . A combination for use according to any one of the preceding claims, wherein the leucine source comprises at least 12 wt %, more preferably 15 wt % of leucine most preferably more than 18 wt % of leucine based on total proteinaceous matter. 
     
     
         11 . A nutritional composition, a pharmaceutical composition or a nutraceutical composition comprising a combination of a leucine source and an ω-3 polyunsaturated fatty acid source for use according to any one of the preceding claims. 
     
     
         12 . A composition for use according to  claim 11 , comprising at least one carbohydrate, in particular at least one oligosaccharide. 
     
     
         13 . A composition for use according to  claim 12 , wherein the composition comprises at least one oligosaccharide selected from the group of galactooligosaccharides and fructooligosaccharides. 
     
     
         14 . A composition for use according to  claim 11 ,  12  or  13 , comprising at least 15 g/kg total leucine, based on total weight of proteinaceous matter, fat, carbohydrates plus dietary fibres, of the composition, in particular 30 to 70 g/kg leucine, more in particular 40 to 60 g/kg leucine. 
     
     
         15 . A composition for use according to any one of the  claims 11 - 14 , comprising at least 15 g/kg free leucine, based on total weight of proteinaceous matter, fat, carbohydrates plus dietary fibres, of the composition, in particular 22 to 35 g/kg free leucine, more in particular 30 to 35 g/kg free leucine. 
     
     
         16 . A composition for use according to any one of the  claims 11 - 15 , having an ω-3 polyunsaturated fatty acid content, based on total lipids, of at least 12 wt. %, preferably of 18 wt. % or more. 
     
     
         17 . A composition for use according to any one of the  claims 11 - 16 , wherein the composition comprises a marine oil or a fraction thereof, which marine oil or fraction thereof provides at least 70 wt. % of the total of ω-3 polyunsaturated fatty acids in the composition. 
     
     
         18 . A composition for use according to any one of the  claims 11 - 17 , wherein the composition is a nutritional composition having a glycemic index of less than 55, in particular of less than 45. 
     
     
         19 . A combination for use according to any one of the  claims 1 - 10  or a composition for use according to any of the  claims 11 - 18 , for use in the treatment of a human.